Reported 12 months ago
Taipei, July 1, 2024 - The Taiwan Stock Exchange successfully welcomed more companies in the biotech and medical fields to go public and head towards the international stage. Three biotech companies were invited to share their reasons for choosing Taiwan over the US for IPOs, citing lower listing costs and more flexible regulatory standards post-IPO. The exchange offers the Main Board and the Innovation Board, each catering to different company profiles based on core criteria like capital and profitability (Main Board) or market value and growth potential (Innovation Board).
Source: YAHOO